Evonik
$EVK (+0.84%) is planning a reorganization that will separation of hundreds employees.

The specialty chemicals group intends to sell peripheral areas with sales of around 350 million euros and to concentrate on its core businesses in the areas of Coating & Adhesive Coating & Adhesive Resins and Health Care.

In the Health Care segment, the focus is on lipids for mRNA and gene therapies.

The production of keto acids in Hanau is to be completed by the end of 2025 which would mean around 260 employees.

Two sites in France 🇫🇷 and China 🇨🇳 are also up for sale.

The Coating & Adhesive Resins division will focus on liquid polybutadienes and specialty acrylates, while other divisions will also be put up for sale. Currently, the C4 composite business with over 1000 employees and the polyolefins business with sales of around 100 million euros and around 150 employees for sale. -Handelsblatt

Photo: Evonik Industries AG